検索
Aligos Therapeutics Inc
ALGSウォッチリストに追加
5.240USD
+0.070+1.35%
終値 09-18 16:00（ET）
32.31M時価総額
損失額直近12ヶ月PER
詳細情報 Aligos Therapeutics Inc 企業名
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Aligos Therapeutics Inc プロフィール
企業コードALGS
会社名Aligos Therapeutics Inc
上場日Oct 16, 2020
最高経営責任者「CEO」Blatt (Lawrence M)
従業員数70
証券種類Ordinary Share
決算期末Oct 16
本社所在地One Corporate Dr., 2Nd Floor
都市SOUTH SAN FRANCISCO
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号94080
電話番号18004666059
ウェブサイトhttps://www.aligos.com/
企業コードALGS
上場日Oct 16, 2020
最高経営責任者「CEO」Blatt (Lawrence M)
Aligos Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President and Chief Executive Officer
Chairman of the Board, President and Chief Executive Officer
88.42K
--
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
35.11K
+55.11%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Executive Vice President, Chief Operating Officer and Chief Financial Officer
Executive Vice President, Chief Operating Officer and Chief Financial Officer
5.22K
+30.85%
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Ms. Carole L. Nuechterlein, J.D.
Ms. Carole L. Nuechterlein, J.D.
Independent Director
Independent Director
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Mr. Jordyn Tarazi
Mr. Jordyn Tarazi
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Dr. Heather Preston, M.D.
Dr. Heather Preston, M.D.
Independent Director
Independent Director
--
--
Ms. Margarita Chavez, J.D.
Ms. Margarita Chavez, J.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President and Chief Executive Officer
Chairman of the Board, President and Chief Executive Officer
88.42K
--
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
35.11K
+55.11%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Executive Vice President, Chief Operating Officer and Chief Financial Officer
Executive Vice President, Chief Operating Officer and Chief Financial Officer
5.22K
+30.85%
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Ms. Carole L. Nuechterlein, J.D.
Ms. Carole L. Nuechterlein, J.D.
Independent Director
Independent Director
--
--
よくある質問
Aligos Therapeutics Incの上位5名の株主は誰ですか？
Aligos Therapeutics Incの上位5名の株主は以下のとおりです。Dr. Lawrence M. Blatt, Ph.D.
Aligos Therapeutics Inc（ALGS）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Aligos Therapeutics Incの株式を保有している機関は108社あり、保有株式の総市場価値は約2.82Mで、全体の52.29%を占めています。2025Q4と比較して、機関の持ち株は-1521590.00増加しています。